

Written responses to open questions of the webinar 'Project management in antimicrobial drug R&D' by Kristina Orrling (speaker) and Sina Gerbach (moderator), originally broadcast on 7 June 2023.

See webinar recording here: <https://revive.gardp.org/project-management-in-antimicrobial-drug-rd/>

Question asked	Response from the speakers
Please shed some light on conflict resolution in international collaboration; keeping the fact alive regarding the geographical variation in AMR.	It is important to understand what type of conflict it is. Does it originate from a tactical, procedural, or a systemic issue. Depending on the nature, they will be tackled in different ways. It is the responsibility of the project management team to ensure that everybody's opinions are heard and respected.
Can you comment more on the quality element in the scope?	Quality in R&D projects can be interpreted as the scientific excellence, e.g., how many clinical sites, cohorts and patients are included in a trial; the stringency of selection criteria of research compounds; the number, diversity, and innovation-level of the assays used to achieve the objectives.
What strategies do you have for communicating realistic timelines to management/investors without coming off as a pessimist or demotivating the team. This question relates to the point made about things taking longer than most anticipate at the beginning of a project (The Bill Gates quote)	Celebrating early progress is very important to maintain enthusiasm and commitment. This is closely related to the project planning and indicating deliverables and milestones to facilitate (internal) communication of breakthroughs.
Do you have any example of effective tool/technique to align different cultures and promote cooperation despite personal believes?	This is a big question fit for its own webinar! Three actions I recommend: 1) Organise a kick-off meeting at the start of the project and make sure as many as possible representatives of the project partners join. 2) Ask the question "How will you contribute to the project" to all attendees (in breakout groups of 5-10 people). 3) Organise a team-building activity at the beginning of the project, but also at times of turbulence.
Could you elaborate on how competitors can provide benefits and opportunities?	Every competitor is a potential collaboration partner, especially in a resource-limited field such as AMR. In addition, competition is likely to increase the awareness for the issue/solution, may force you to sharpen your innovation value-proposition, and spur the team to more creative thinking.

Remaining audience questions from the webinar 'Project management in antimicrobial drug R&D' by Kristina Orrling and Julie Miralves, originally broadcast on 7 June 2023

Question asked	Response from the speakers
<p>Thank you very much to both speakers, excellent talks.            Question: How would one typically launch a collaboration with Lygature for getting project management support?</p>	<p>The conversation for engaging Lygature for project management typically occurs at the idea or early proposal phase. More concretely, please send me an email and I'll explain more <a href="mailto:Kristina.orriling@lygature.org">Kristina.orriling@lygature.org</a></p>
<p>Does INCATE mostly focus on drug discovery/development?</p>	<p>INCATE supports specifically antimicrobial resistance (AMR)-related innovations (TRL 1-4). INCATE addresses particularly the problem of an insufficient flow of early innovation by supporting the transfer of academic discoveries to investible biotech startups and creating a viable ecosystem encouraging young investigators particularly in the AMR-field (antimicrobial resistance), which suffers due to poor economical attractiveness, while innovative antimicrobial concepts are desperately sought after. The goal is to cure currently insufficient clinical development pipelines with urgently needed antimicrobial concepts to waive the global danger of resistant pathogens.</p>

Remaining audience questions from the webinar 'Project management in antimicrobial drug R&D' by Kristina Orrling and Julie Miralves, originally broadcast on 7 June 2023